# A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

> **NCT03019536** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 22 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** LY3303560 - IV
- **DRUG:** Placebo - IV
- **DRUG:** Florbetapir F 18
- **DRUG:** Flortaucipir F18

## Key facts

- **NCT ID:** NCT03019536
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2019-06-05
- **Final completion:** 2019-06-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019536, "A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03019536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*